- Home
- FOXX vs STTK Comparison
FOXX vs STTK Comparison
Compare FOXX & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOXX
- STTK
- Stock Information
- Founded
- FOXX 2017
- STTK 2016
- Country
- FOXX United States
- STTK United States
- Employees
- FOXX N/A
- STTK N/A
- Industry
- FOXX
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- FOXX
- STTK Health Care
- Exchange
- FOXX Nasdaq
- STTK Nasdaq
- Market Cap
- FOXX 33.5M
- STTK 36.2M
- IPO Year
- FOXX N/A
- STTK 2020
- Fundamental
- Price
- FOXX $5.32
- STTK $0.83
- Analyst Decision
- FOXX
- STTK Hold
- Analyst Count
- FOXX 0
- STTK 4
- Target Price
- FOXX N/A
- STTK $3.00
- AVG Volume (30 Days)
- FOXX 13.4K
- STTK 305.5K
- Earning Date
- FOXX 05-15-2025
- STTK 05-01-2025
- Dividend Yield
- FOXX N/A
- STTK N/A
- EPS Growth
- FOXX N/A
- STTK N/A
- EPS
- FOXX N/A
- STTK N/A
- Revenue
- FOXX $42,988,015.00
- STTK $5,721,000.00
- Revenue This Year
- FOXX N/A
- STTK N/A
- Revenue Next Year
- FOXX N/A
- STTK N/A
- P/E Ratio
- FOXX N/A
- STTK N/A
- Revenue Growth
- FOXX 98.81
- STTK 245.26
- 52 Week Low
- FOXX $2.45
- STTK $0.69
- 52 Week High
- FOXX $14.99
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- FOXX N/A
- STTK 44.82
- Support Level
- FOXX N/A
- STTK $0.73
- Resistance Level
- FOXX N/A
- STTK $0.90
- Average True Range (ATR)
- FOXX 0.00
- STTK 0.15
- MACD
- FOXX 0.00
- STTK 0.00
- Stochastic Oscillator
- FOXX 0.00
- STTK 19.96
About FOXX Foxx Development Holdings Inc. Common Stock
Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.